Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib

Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non‐small cell lung cancer (NSCLC). Here, we report the case of a 60‐year‐old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combina...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yuan, Yu, Qing, Xiong, Yan, Guo, Cuiyan, Nie, Ligong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919124/
https://www.ncbi.nlm.nih.gov/pubmed/33438350
http://dx.doi.org/10.1111/1759-7714.13785
_version_ 1783658073824428032
author Cheng, Yuan
Yu, Qing
Xiong, Yan
Guo, Cuiyan
Nie, Ligong
author_facet Cheng, Yuan
Yu, Qing
Xiong, Yan
Guo, Cuiyan
Nie, Ligong
author_sort Cheng, Yuan
collection PubMed
description Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non‐small cell lung cancer (NSCLC). Here, we report the case of a 60‐year‐old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertinib due to elevated mesenchymal epithelial transition (MET) copy number amplification. However, early‐onset interstitial pneumonitis occurred within two days.
format Online
Article
Text
id pubmed-7919124
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-79191242021-03-05 Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib Cheng, Yuan Yu, Qing Xiong, Yan Guo, Cuiyan Nie, Ligong Thorac Cancer Case Reports Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non‐small cell lung cancer (NSCLC). Here, we report the case of a 60‐year‐old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertinib due to elevated mesenchymal epithelial transition (MET) copy number amplification. However, early‐onset interstitial pneumonitis occurred within two days. John Wiley & Sons Australia, Ltd 2021-01-12 2021-03 /pmc/articles/PMC7919124/ /pubmed/33438350 http://dx.doi.org/10.1111/1759-7714.13785 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Cheng, Yuan
Yu, Qing
Xiong, Yan
Guo, Cuiyan
Nie, Ligong
Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib
title Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib
title_full Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib
title_fullStr Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib
title_full_unstemmed Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib
title_short Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib
title_sort early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919124/
https://www.ncbi.nlm.nih.gov/pubmed/33438350
http://dx.doi.org/10.1111/1759-7714.13785
work_keys_str_mv AT chengyuan earlyonsetinterstitialpneumonitisinapatientwithadvancednonsmallcelllungcancertreatedwithcrizotinibandosimertinib
AT yuqing earlyonsetinterstitialpneumonitisinapatientwithadvancednonsmallcelllungcancertreatedwithcrizotinibandosimertinib
AT xiongyan earlyonsetinterstitialpneumonitisinapatientwithadvancednonsmallcelllungcancertreatedwithcrizotinibandosimertinib
AT guocuiyan earlyonsetinterstitialpneumonitisinapatientwithadvancednonsmallcelllungcancertreatedwithcrizotinibandosimertinib
AT nieligong earlyonsetinterstitialpneumonitisinapatientwithadvancednonsmallcelllungcancertreatedwithcrizotinibandosimertinib

Ejemplares similares